Search

Displaying results 1741 - 1750 of 10000 in total
  1. Drug

    PRGN-3006

    go.drugbank.com/drugs/DB17229
    Investigational

    PRGN-3006 are autologous CD3+ T cells genetically modified using a non-viral system to express a CD33 CAR, membrane-bound interleukin-15, and a truncated form of human HER1T (kill switch) on the cell surface

    Synonyms: Autologous CD3+ T cells genetically modified using a non-viral system to express a CD33 CAR, membrane bound Interleukin-15, and a truncated form of human HER1t (kill switch) on the cell surface
  2. Indication

    Chronic Back Pain

    go.drugbank.com/conditions/DBCOND0057664
    Drugs: Etodolac · Famotidine · Flurbiprofen · Thiocolchicoside
    Synonyms: Pain in back
  3. Indication

    Scaling

    go.drugbank.com/conditions/DBCOND0094899
    Drugs: Salicylic acid
    Synonyms: Changes in skin texture
  4. Drug

    Flortaucipir F-18

    go.drugbank.com/drugs/DB14914
    ApprovedInvestigational

    It was approved by the FDA on May 28, 2020, for sale by Avid Radiopharmaceuticals under the name TAUVID™ and is the first FDA-approved molecule for imaging aggregated tau protein in the brain.[L14114] … [A203933] It is used as a marker in positron emission tomography (PET) imaging of patients suspected of having Alzheimer's disease.

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Remestemcel-L

    go.drugbank.com/drugs/DB13973
    ApprovedInvestigationalWithdrawn

    It was approved for use in Canada in May 2012 as Prochymal for the management of refractory acute Graft versus Host Disease (aGvHD) in children who are unresponsive to systemic steroid therapies, with … Remestemcel-L is a third-party, off-the-shelf suspension of ex-vivo cultured adult human mesenchymal stem cells intended for intravenous infusion.

  6. Drug

    Inebilizumab

    go.drugbank.com/drugs/DB12530
    ApprovedInvestigational

    [A214280, A214295] On January 16, 2024, inebilizumab also received Health Canada approval for the same indication. … [L49861] In April 2025, inebilizumab was additionally approved by the FDA for immunoglobulin G4-related disease (IgG4-RD).[L52705,L14315] It is the first and only FDA-approved treatment for IgG4-RD.

  7. Drug

    Bempedoic acid

    go.drugbank.com/drugs/DB11936
    ApprovedInvestigational

    A combination product of bempedoic acid and [ezetimibe] was approved on February 26, 2020 for increased control of LDL cholesterol levels in patients experiencing refractory elevations despite previous … [L12180] Bempedoic acid is first-in-class adenosine triphosphate-citrate lyase (ACL) inhibitor used once a day for reducing LDL cholesterol levels in statin-refractory patients.

    Categories: Non-statin Hypolipidemic Agents Indicated for Hyperlipidemia, Hypolipidemic Agents Indicated for Hyperlipidemia
  8. Drug

    Nialamide

    go.drugbank.com/drugs/DB04820
    ApprovedWithdrawn

    Withdrawn from the Canadian, US, and UK markets in 1963 due to interactions with food products containing tyrosine.

    Categories: Monoamine Oxidase Inhibitors, Non-Selective, Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeSynonyms: N-Isonicotinoyl-N'(beta-N-benzylcarboxamidoethyl)hydrazine, N-(2-(Benzylcarbamyl)ethylamino)isonicotinamide
  9. Indication

    Lower Back Pain

    go.drugbank.com/conditions/DBCOND0030634
    Drugs: Benzyl nicotinate · Capsaicin · Eperisone · Ethyl salicylate · Glycol salicylate · Horse chestnut +8 more
    Synonyms: Pain in back, Nonspecific pain in the lumbar region
  10. Drug

    Lorlatinib

    go.drugbank.com/drugs/DB12130
    ApprovedInvestigational

    Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer[L39905] which was first approved by the US FDA in November of 2018 … It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to